Annual MPNE conference for European Melanoma advocates

​22nd- 24th March 2019

arrival 22nd in the morning, we start early in the afternoon


Location 

Brussels 


MPNEhubs- invitation only

Thursday, 21st March 

19.30 MPNE hubs working dinner 

Friday, 22nd March
8.00- 12.00 MPNEhubs


Friday, 22nd March

13.30- 14.00

QuickStart to MPNE2019, especially recommended for MPNE new-comers


Welcome to the conference and MPNE

Bettina Ryll


Melanoma in a nutshell

Bettina Ryll


Know your stage!

The Melanoma stage defines treatment options and prognosis, so is critical to understand. This is the compressed MPNE version on staging!

Violeta Astratinei and Gilly Spurrier, MPNE


MPNE 2019- the short version

What to expect from this weekend with brief introduction to sessions

Fredrik Östman and Bettina Ryll, MPNE


14.00- 15.00
Welcome Coffee

Meet your colleagues and time to hang up your posters! 


Parallel session program- under development 


15.00- 15.50

Session- The immune system in Melanoma

An introduction to the immune system: what it does, the main players involved, what are checkpoints and why do they matter? 

16.00- 16.50

Session- Imaging explained
Imaging is an important part of the diagnosis, surveillance and treatment control in Melanoma. Understand what the different imaging modalities are, how they work and what their advantages and disadvantages are.
Luc Vautmans, Belgium 


OM- Beauty is in the eye of the beholder: eye anatomy in depth
Guilherme Neri Pires, Ophthalmological surgeon, Lisbon, Portugal

Martina Rooijakkers, Stichting Melanoom, Netherlands


Histopathology

What does a pathologist do and what happens to your samples? 


17.00- 18.30

Session- Famously infamous: Melanoma's heterogeneity

Melanoma is famous for its heterogeneity. The same tumour can have different areas (intra-tumour heterogeneity), within the same patients, tumours can  differ from each other (inter-tumour heterogeneity) and then, there seems some organ-site specificity with brain and liver mets notoriously hard to treat- why does this matter, where does it come from and which consequences has this for how patients are diagnosed, treated and respond to treatment?


18.30- 19.00 Fireside chat

The future in Melanoma



19.15 

Advocacy Speed Dating with Tom tbc

get to meet the network in a fast & fun way


20:00 Dinner



Saturday, 23rd March


8.00- 9.00 Breakfast 


9.00- 10.30
Session- What to do when therapies fail? Understanding resistance to therapies

Unfortunately, not all Melanoma patients respond to therapies and some respond initially but then develop resistance. Understand the concepts of primary and acquired resistance and the current thinking about strategies how to overcome those. What are the next promising treatments in the pipeline? 



10.30- 11.00 Coffee


11.00- 12.30

Session- Melanoma: what's in the pipeline?

Neo-epitope specific TCR (T-cell receptor) gene therapy

John Haanen, NKI, Netherlands


13.00- 14.00 Lunch

14.30- 16.00

Session- The latest about clinical trials as ACCESS to new therapies- Drugs only work in patients who (get to) take them (early enough). 
Progress in Melanoma therapies has been phenomenal- however, at the edge, where need is highest and patients are out of other options, access was and remains a constant struggle. This session will focus on how to find out which therapies are promising, understand what clinical trial designs really mean for you and how to access them. 


Accessing clinical trials abroad- a recent experience

Erik Näsman, Sweden, confirmed

The Dutch experience- learnings from the Dutch Melanoma Treatment Registry

Michiel van Zeijl (invited)

 

16.00- 16.30 Coffee

16.30- 18.00

Session- clinical trial designs of the future

Trial designs for Melanoma patients
Bettina Ryll

What's new in regulatory Science?

speaker tbc

Clinical trial design and issues for HTA
Alric Ruther, IQWiG, Germany



18.00

The power of a network- knowledge for all

After last year's success: more about how to read scientific publications. 

Introduction to how to read a scientific publication and how the ESMO MCBS tool can help you with that

We will then read relevant Melanoma publications in groups and summarise them in a form that we can easily share with the wider Melanoma community- knowledge protects. 


And obviously, we shall end with another MPNE Kahoot!


19.00 Poster competition and Reception

Present your favourite Melanoma advocacy project- past, present and future- on a poster! 


20.00 Conference Dinner 


Sunday, 24th March
Advocacy Day 


8.00- 9.00

Breakfast

please make sure you check out


9.00- 10.30

Session: Advocacy concepts

Get inspired with new ideas and concepts what patient advocacy can actually look like and get an update about the network's activities and plans for 2019 


What patients know only patients know- how a researcher went to find out.

Emma Dorris, UCD, Ireland, invited


MPNE update

Bettina Ryll, MPNE


10.30- 11.00 Coffee


11.00- 12.30

Session: The best of the network in 2018

Listen to what your colleagues have been up to in the last year!

Abstract-based session- info to come shortly



12.30- 12.45

Conference summary and closure
Bettina Ryll, MPNE

13.00

Lunch and Departure



afternoon

ECAB meeting tbc

Work in progress- please come back to check for updates and don't trust any times right now- they will change!!!

Program 

MPNE 2019 22nd- 24th March 2019 


10th January 2019 BR


Surviving Melanoma in Europe.  

Access to prevention, early detection and effective treatment for all.

Melanoma Patient Network Europe

However, if you want to watch program development in real-time, watch the space!!